Adult: As 0.0015% soln: Instill 1 drop in the conjunctival sac of the affected eye(s) once daily, preferably in the evening.
Thận trọng
Patient w/ active intraocular inflammation (e.g. uveitis, iritis), aphakia, pseudoaphakia w/ torn posterior lens capsule, risk factors for cystoid macular oedema, history of herpetic keratitis, severe asthma. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Macular oedema, pigmentation of the iris, eyelid, and eyelashes; eyelash changes. Nervous: Headache. Resp: Cough, common cold, asthma exacerbation, dyspnoea. Genitourinary: UTI. Ophthalmologic: Conjunctival hyperaemia, allergic conjunctivitis, blurred vision, blepharitis, punctate keratitis, eyelid and conjunctival oedema, dry eye, iritis, uveitis, cataract, ocular pain, eye irritation (e.g. stinging, grittiness, itching), reactivation of herpetic keratitis.
This drug may cause transient blurring of vision upon instillation, wait until vision clears before driving or operating machinery. May change the colour of the iris, eyelid, and eyelashes; may also cause thickening and lengthening of the eyelashes. Avoid contact w/ skin as it may lead to hair growth or skin pigmentation.
Chỉ số theo dõi
Monitor IOP. Regularly examine patients who develop increased iris pigmentation.
Tương tác
Paradoxical increase in IOP may occur when used w/ other ocular prostaglandin analogues.
Tác dụng
Description: Mechanism of Action: Tafluprost is a prodrug of tafluprost acid, a fluorinated prostaglandin F2α analogue. The exact mechanism by which it reduces intraocular pressure (IOP) is unknown, but is believed to act by increasing the uveoscleral outflow of aqueous humour. Onset: Reduction of IOP: 2-4 hr. Duration: ≥24 hr. Pharmacokinetics: Absorption: Absorbed through the cornea. Time to peak plasma concentration: Approx 10 min. Metabolism: Metabolised via hydrolysis to the biologically active metabolite, tafluprost acid, which is metabolised further via fatty acid β-oxidation and phase II conjugation. Excretion: Via urine (approx 27-38%) and faeces (approx 44-58%).
Đặc tính
Tafluprost Source: National Center for Biotechnology Information. PubChem Database. Tafluprost, CID=9868491, https://pubchem.ncbi.nlm.nih.gov/compound/Tafluprost (accessed on Jan. 23, 2020)
S01EE05 - tafluprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
Tài liệu tham khảo
Anon. Tafluprost. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/05/2017 .Buckingham R (ed). Tafluprost. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/05/2017 .Joint Formulary Committee. Tafluprost. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/05/2017 .McEvoy GK, Snow EK, Miller J et al (eds). Tafluprost (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 03/05/2017 .Zioptan Solution/Drops (Akorn, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/05/2017 .
Đăng xuất
